Core Viewpoint - Lide Health Technology (Guangzhou) Co., Ltd. has successfully completed a multi-million yuan Pre-A round financing, aiming to enhance its capabilities in AI life science instruments and biomanufacturing equipment, aligning with national strategic goals in the "14th Five-Year Plan" [4][8]. Group 1: Company Overview - Since its operation began in March 2024, Lide Health has established a multidisciplinary team of over 100 members, with more than 60% being R&D personnel, covering various fields such as AI, optics, mechanics, and biology [5]. - The company has launched over 10 high-end AI life science instruments and services, including AI models for cell identification and high-throughput imaging systems, addressing inefficiencies and high costs in traditional life sciences [5][6]. Group 2: Future Product Development - Lide Health plans to continue developing competitive product solutions, including virtual cell AI models and high-throughput drug screening systems, to provide large-scale, high-quality data production tools for the AI for Science sector [6]. - The company has built several innovative laboratories to prepare for large-scale production and delivery of its products [6]. Group 3: Intellectual Property and Standards - Lide Health has applied for over 110 patents, with around 50% being invention and PCT international patents, and has been recognized as an excellent case for patent transformation by the National Intellectual Property Administration [7]. - The company has participated in the formulation of 26 standards, including 7 national standards, promoting the automation and intelligent transformation of the life sciences sector [7]. Group 4: Investment and Market Position - The lead investor in the Pre-A round highlighted Lide Health's exceptional technological innovation and industrialization capabilities, aligning with national strategic directions and industry trends [8]. - The company has signed contracts worth several million yuan with nearly 100 leading clients, including top universities, research institutions, and major biopharmaceutical companies [6].

Core Insights - The article highlights the successful angel round financing of Lide Health Technology, raising nearly 100 million RMB, marking the largest angel financing in the life sciences and bio-manufacturing equipment sector in the past three years [2] - Lide Health, established in October 2023, focuses on AI and high-end life science instruments, aiming to provide microfluidic, automation, and intelligent system-level solutions for various fields [4] - The company has signed a cooperation agreement with Guangzhou Laboratory for the transformation of 22 patents, including several PCT international patents and invention patents, and has independently applied for 57 patents and 10 software copyrights [4] Company Overview - Lide Health is headquartered in Guangzhou International Biological Island and specializes in the research and development of high-end life science instruments and bio-manufacturing equipment [4] - The company has quickly achieved commercialization of technological achievements, signing commercial orders exceeding 10 million RMB with leading clients in 2024 [4] Core Technologies and Products - Lide Health's core technologies span microfluidic chips, life sciences, biopharmaceuticals, medical devices, robotic automation, and artificial intelligence [5] - The company has developed a series of proprietary products, including a single-cell multi-omics system and a high-throughput AI imaging flow cytometer, which are crucial for life science research and biopharmaceuticals [5][6] - The active single-cell sequencing system is a pioneering product in the industry, featuring active coding sorting technology and excellent sample compatibility [5] Upcoming Events - The article mentions several upcoming global medical technology conferences organized by Suyu, including the first Global Aesthetic Technology Conference on June 12, 2025, and the second Global Medical Technology Conference on July 17, 2025 [1][7]